Neoadjuvant chemotherapy and DTI-reconstruction in breast cancer patients

Zikiryakhodzhaev A.D., Bosieva A.R.

1) P.A. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Center, Ministry of Health of Russia, Moscow, Russia; 2) Peoples’ Friendship University of Russia, Moscow, Russia; 3) I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), Department of Oncology, Radiotherapy and Plastic Surgery, Moscow, Russia

Neoadjuvant polychemotherapy (NACT) is currently the cornerstone in the treatment of locally advanced breast cancer (BC) and highly chemosensitive tumors, such as triple-negative and HER/neu-positive types. The lack of clear consensus on the optimal method of breast reconstruction after NACT has resulted in a wide variety of techniques used in practice. The factors which influence the choice of surgical intervention also remain unclear.
The databases and systems, namely PubMed, Cochrane Library, eLibrary have been searched for articles published from 2012 to 2023; this review includes the results of 27 studies.
The information about the possibility of performing and expanding indications for organ-preserving treatment, performing reconstructive plastic surgery, including one-stage reconstructions using allomaterials after NACT reflects current national and global trends in the treatment of patients with breast cancer. When performing a one-stage reconstruction, various methods of reconstruction can be used: reconstruction with own tissues, reconstruction with the use of allomaterials, reconstruction with a thoracodorsal flap in combination with an endoprosthesis/tissue expander, etc. There are the following indications for performing a mastectomy with one-stage or two-stage reconstruction after NACT: the absence of a tumor response to NACT (NR); in case of a partial response, the ratio of the size of the residual tumor and the size of the breast does not allow performing an organ–preserving operation (OPO) and, therefore, achieving a satisfactory aesthetic result; if an interstitial marker is not placed in the tumor node before NACT (in CR and PR); the patient does not want an OPO, but at the same time she has a wish to maintain a satisfactory aesthetic result after surgery.
Conclusion: Performing one-stage breast reconstruction using allomaterials (DTI-reconstruction) is safe in term of oncology and it does not increase the incidence of surgical complications. The esthetic results of the operation are also comparable with similar parameters of patients who did not undergo NACT at the first stage.

Authors’ contributions: Zikiryakhodzhaev A.D., Bosieva A.R. – developing the concept and design of the study; Bosieva A.R. –  collecting and processing data, writing the text; Zikiryakhodzhaev A.D. – editing the text.
Conflicts of interest: Authors declare lack of the possible conflicts of interest.
Funding: The study was conducted without sponsorship.
For citation: Zikiryakhodzhaev A.D., Bosieva A.R. Neoadjuvant chemotherapy and DTI-reconstruction in breast cancer patients.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2024; (2): 31-36 (in Russian)


breast cancer
neoadjuvant chemotherapy
one-stage breast reconstruction


  1. Бересток Т.С., Зикиряходжаев А.Д., Ермощенкова М.В., Аблицова Н.В., Онофрийчук И.М., Власова М.Ю., Трошенков Е.А. Осложнения после одномоментной одноэтапной и двухэтапной реконструкции имплантатами у больных раком молочной железы при проведении комбинированного/комплексного лечения. Онкология. Журнал им. П.А. Герцена. 2023; 12(3): 54-61. [Berestok T.S., Zikiryakhodzhaev A.D., Ermoshchenkova M.V., Ablitsova N.V., Onofriychuk I.M., Vlasova M.Yu., Troshenkov E.A. Complications after simultaneous one-stage and two-stage reconstruction with implants in patients with breast cancer during combined/combination treatment. P.A. Herzen Journal of Oncology. 2023; 12(3): 54-61. (in Russian)].
  2. Зикиряходжаев А.Д., Фролова М.А., Рассказова Е.А., Глазкова Е.В. Лечение тройного негативного подтипа рака молочной железы. Опухоли женской репродуктивной системы. 2017; 13(2): 20-6. [Zikiryakhodzhaev A.D., Frolova M.A., Rasskazova E.A., Glazkova E.V. Treatment of triple-negative breast cancer. Tumors of Female Reproductive System. 2017; 13(2): 20-6. (in Russian)].
  3. Токаев В.К., Зикиряходжаев А.Д., Трошенков Е.А., Рассказова Е.А., Поляк М.А., Никитина Е.А., Малик Д.С. Реконструктивно-пластические операции у больных раком молочной железы со стадиями T1-3N1-3M0. Современная наука: актуальные проблемы теории и практики. Серия: Естественные и технические науки. 2023; 3: 242-8. [Tokaev V.K., Zikiryahodzhaev A.D., Troshenkov E.A., Rasskazova E.A., Polyak M.A., Nikitina E.A., Malik DS. Reconstructive plastic surgery in patients with breast cancer stages T1-3N1-3M0. Modern Science: Actual Problems of Theory and Practice. Series "Natural and Technical Sciences". 2023; (3): 242-8. (in Russian)].–2966.2023.03.36.
  4. Cardoso F., Kyriakides S., Ohno S., Penault-Llorca F., Poortmans P., Rubio I.T. et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2019; 30(8): 1194-220.
  5. Burstein H.J., Curigliano G., Loibl S., Dubsky P., Gnant M., Poortmans P. et al. Estimating the benefits of therapy for early-stage breast cancer: The St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann. Oncol. 2019; 30(10): 1541-57.
  6. Puig C.A., Hoskin T.L., Day C.N., Habermann E.B., Boughey J.C. National trends in the use of neoadjuvant chemotherapy for hormone receptor-negative breast cancer: A National Cancer Data Base Study. Ann. Surg. Oncol. 2017; 24(5): 1242-50.
  7. Killelea B.K., Yang V.Q., Mougalian S., Horowitz N.R., Pusztai L., Chagpar A.B., Lannin D.R. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J. Am. Coll. Surg. 2015; 220(6): 1063-9.
  8. Mougalian S.S., Soulos P.R., Killelea B.K., Lannin D.R., Abu-Khalaf M.M., DiGiovanna M.P. et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015; 121(15): 2544-52.
  9. Franceschini G., Di Leone A., Natale M., Sanchez M.A., Masett R. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer. Ann. Ital. Chir. 2018; 89: 290.
  10. von Minckwitz G., Huang C.-S., Mano M.S., Loibl S., Mamounas E.P., Untch M. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 2019; 380(7): 617-28.
  11. Parmar V., Krishnamurthy A., Hawaldar R., Nadkarni M.S., Sarin R., Chinoy R. Breast conservation treatment in women with locally advanced breast cancer—experience from a single centre. Int. J. Surg. 2006; 4(2): 106-14.
  12. von Minckwitz G. Preoperative therapy: what, when and for whom? Ann. Oncol. 2008l; 19(Supppl 5): v113-6.
  13. Hunt K.K., Yi M., Mittendorf E.A., Guerrero C., Babiera G.V., Bedrosian I., Hwang R.F. et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann. Surg. 2009; 250(4): 558-66.
  14. Cen C., Chun J., Kaplowitz E., Axelrod D., Shapiro R., Guth A., Schnabel F. Margin assessment and re-excision rates for patients who have neoadjuvant chemotherapy and breast-conserving surgery. Ann. Surg. Oncol. 2021; 28(9): 5142-8.
  15. Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R. et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 1998; 16(8): 2672-85.
  16. Conti M., Morciano F., Bufi E., D'Angelo A., Panico C., Di Paola V. et al. Surgical planning after neoadjuvant treatment in breast cancer: a multimodality imaging-based approach focused on MRI. Cancers (Basel). 2023; 15(5): 1439.
  17. Monrigal E. Mastectomy with immediate breast reconstruction after neoadjuvant chemotherapy and radiation therapy. A new option for patients with operable invasive breast cancer. Results of a 20 years single institution study. Eur. J. Surg. Oncol. 2011; 37(10): 864-70.
  18. Donker M., Hage J.J., Woerdeman L.A.E., Rutgers E.J.T., Sonke G.S. Surgical complications of skin sparing mastectomy and immediate prosthetic reconstruction after neoadjuvant chemotherapy for invasive breast cancer. Eur. J. Surg. Oncol. 2012; 38(1): 25-30.
  19. Chi W., Zhang Q., Li L., Chen M., Xiu B., Yang B., Wu J. Immediate breast reconstruction after neoadjuvant chemotherapy: factors associated with surgical selection and complications. Ann. Plast. Surg. 2023; 91(1): 48-54.
  20. Jagsi R., Momoh A.O., Qi J., Hamill J.B., Billig J., Kim H.M. et al. Impact of radiotherapy on complications and patient-reported outcomes after breast reconstruction. J. Natl. Cancer Inst. 2018; 110(2): 157-65.
  21. Beugels J., Bod L., van Kuijk S.M.J., Qiu S.S., Tuinder S.M.H., Heuts E.M. et al. Complications following immediate compared to delayed deep inferior epigastric artery perforator flap breast reconstructions. Breast Cancer Res. Treat. 2018; 169(2): 349-57.
  22. Ishiba T., Aruga T., Miyamoto H., Ishihara S., Nara M., Adachi M. et al. Short- and long-term outcomes of immediate breast reconstruction surgery after neoadjuvant chemotherapy. Surg. Today. 2022; 52(1): 129-36.
  23. Naoum G.E., Oladeru O.T., Niemierko A., Salama L., Winograd J., Colwell A. et al. Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy. Breast Cancer Res, Treat. 2020; 183(1): 127-36.
  24. Sabitovic A., Trøstrup H., Damsgaard T.E. The impact of neoadjuvant chemotherapy on surgical outcomes following autologous and implant-based immediate breast reconstruction: a systematic review and meta-analysis. J. Plast. Reconstr. Aesthet. Surg. 2023; 87: 17-23.
  25. Yang J.R., Kuo W.L., Yu C.C., Chen S.C., Huang J.J. Reconstructive outcome analysis of the impact of neoadjuvant chemotherapy on immediate breast reconstruction: a retrospective cross-sectional study. BMC Cancer. 2021; 21(1): 522.
  26. Bowen M.E., Mone M.C., Buys S.S., Sheng X., Nelson E.W. Surgical outcomes for mastectomy patients receiving Neoadjuvant chemotherapy: a propensity-matched analysis. Ann. Surg. 2017; 265(3): 448-56.
  27. Beugels J., Meijvogel J.L.W., Tuinder S.M.H., Tjan-Heijnen V.C.G., Heuts E.M., Piatkowski A., van der Hulst R.R.W.J. The influence of neoadjuvant chemotherapy on complications of immediate DIEP flap breast reconstructions. Breast Cancer Res. Treat. 2019; 176(2): 367-75.

Received 08.11.2023

Accepted 24.01.2024

About the Authors

Azizjon D. Zikiryakhodzhaev, Dr. Med. Sci., Professor, Head of the Department of Oncology and Reconstructive Plastic Surgery of the Breast and Skin, P.A. Herzen Moscow Research Institute of Oncology – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia, 125284, Russia, Moscow, 2nd Botkinsky passage, 3; Professor of the Department of Oncology, Radiotherapy and Plastic Surgery, Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University,
Ministry of Health of Russia (Sechenov University), 119991, Russia, Moscow, Trubetskaya str., 8-2; Professor of the Department of Oncology and X-ray Radiology named after
V.P. Kharchenko, Medical Institute, RUDN University, 117198, Russia, Moscow, Miklukho-Maklaya str., 6,,
Alana R. Bosieva, PhD, Researcher at the Department of Oncology and Reconstructive Plastic Surgery of the Breast and Skin, P.A. Herzen Moscow Research Institute of Oncology – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia, 125284, Russia, Moscow, 2nd Botkinsky passage, 3; Assistant at the Department of Oncology and X-ray Radiology named after V.P. Kharchenko, Medical Institute, RUDN University, 117198, Russia, Moscow, Miklukho-Maklaya str., 6, +7(988)875-10-47,, SPIN-code: 1090-7281,
Corresponding author: Alana R. Bosieva,

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.